Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acacia Pharma's Antiemetic Baremsis A Step Closer to US Filing

Executive Summary

Acacia Pharma has taken another step towards filing its post-operative nausea and vomiting treatment Baremsis in the US with a second Phase III trial, this time in the treatment, rather than prevention, of the condition.

You may also be interested in...

More PhIII Success For Acacia's Dopamine Antagonist In PONV

Acacia Pharma's goal of returning dopamine antagonists to the arsenal of treatments available for post-operative nausea and vomiting (PONV) has experienced another boost following positive results from a second Phase III study, this time evaluating the use of lead product Baremsis as a prophylaxis in combination with standard antiemetics for the prevention of PONV in high-risk patients.

Where next for Acacia Pharma on positive PhIII PONV data?

Private UK company Acacia Pharma is hoping to return dopamine antagonists to the arsenal of drugs available for post-operative nausea and vomiting (PONV) following positive top-line results from two Phase III studies of its lead product APD421.

Deal Watch: Bristol Teams Up With Insitro, Sensyne In AI-Directed Collaborations

Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts